SLT Holdings LLC Purchases New Stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

SLT Holdings LLC purchased a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $66,000.

A number of other institutional investors have also recently modified their holdings of ESPR. SJS Investment Consulting Inc. purchased a new stake in Esperion Therapeutics during the fourth quarter worth $55,000. Versor Investments LP purchased a new stake in Esperion Therapeutics during the third quarter worth $44,000. Foundations Investment Advisors LLC boosted its position in Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company’s stock worth $66,000 after purchasing an additional 9,872 shares in the last quarter. J.W. Cole Advisors Inc. purchased a new stake in Esperion Therapeutics during the fourth quarter worth $66,000. Finally, Summit Wealth Group LLC purchased a new stake in Esperion Therapeutics during the third quarter worth $66,000. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have commented on ESPR shares. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a research report on Tuesday, March 4th. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Cantor Fitzgerald assumed coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 price target for the company. Needham & Company LLC reissued a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a report on Friday, December 13th. Finally, JMP Securities reissued a “market outperform” rating and issued a $4.00 price target (down from $7.00) on shares of Esperion Therapeutics in a report on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $6.75.

Esperion Therapeutics Trading Up 6.3 %

Esperion Therapeutics stock opened at $1.69 on Friday. The firm has a market capitalization of $332.99 million, a P/E ratio of -2.64 and a beta of 1.04. The stock has a fifty day moving average price of $1.96 and a 200 day moving average price of $2.08. Esperion Therapeutics, Inc. has a 52 week low of $1.56 and a 52 week high of $3.94.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.